The government said that "in exercise of extraordinary powers in public interest, conferred by paragraph 19 of the DPCO, 2013", the ceiling prices of 21 key formulations had been increased. These formulations include common medicines like BCG vaccines, penicillin, malaria and leprosy medicines (Dapsone), life-saving drugs like Furosemide (used to treat fluid build-up due to heart failure, liver scarring, or kidney disease), vitamin C, some common antibiotics, and anti-allergy medicines.
Even as the Supreme Court had recently dismissed the industry's plea against prices fixed by the regulator and its timely implementation, the National Pharmaceutical Pricing Authority has asked companies to pay the overcharged dues with 15 per cent interest.
A look at the key decisions taken by the Narendra Modi government in its six months.
Ties between India and the United States have been strained in recent years because of trade policies and patent disputes.
India has capped the prices of 36 drugs, including those used to treat infections and diabetes, in its latest move to make essential medicines more affordable, a senior official of the country's drug pricing authority told Reuters on Friday.
.jpg)
The move is expected to delay the introduction of low-priced medicines in the market.
Some of the proposals (for example trade margin calculation for imported medical devices) were not approved by the PMO and were sent back for revisions.
.jpg)
Firms are mandated to change prices of medicines within 45 days of NPPA's notification.
Face NPPA fine for overcharging on anti-asthma drug
NPPA suggests expanding the list of essential medicines whose prices are controlled
Currently, the govt directly caps prices of 348 formulations at the average price of all medicines in a particular segment with at least 1% market share
There may be shortage of drugs till pharmaceutical companies supply new batches with revised MRPs.
Apart from Wockhardt, only Biocon manufactures insulin analog indigenously.
The impact from NELM on the Indian pharmaceutical sector is estimated to be around Rs 6,000 crore.
To keep price control to a minimum, the government can act in two areas where it has not done so far.
Infosys, Wipro and HUL among the top losers for the day.
The latest price revision includes mostly cardiovascular drugs, anti-bacterials, anti-herpes, contraceptives and gastrointestinal medicines
Aneesh Phadnis and Veena Mani find out what the manufacturers and the hospitals have to say.
According to industry estimates, the sector's revenue would increase eight-10 per cent in 2013-14, against 12 per cent in 2012-13.
For the poorest 20 per cent of Indians, the expenditure on medicines alone is 85 per cent of what they spend on their health, according to the National Sample Survey.
Here is some interesting information released by the government in response to questions posed by MPs in Parliament on Tuesday.
In a relief to pharma majors, the Delhi high court today held as "illegal and unsustainable" the Centre's decision to put a ceiling on the price of condoms, including the luxury variety.
The NPPA letter was issued to GSK on Wednesday.
The National Pharmaceutical Pricing Authority will soon notify prices of as many as 150 packs of essential medicines in line with the new pharma pricing policy, according to official sources.
The government plans to rationalise trade margins for many other medical devices, besides stents and knee implants.
Markets recorded their biggest single-day fall since August 1 amid growth concerns in the euro zone.
A probe finds several pharma majors in breach of the law; and in turn they blame the government.
Roadblocks ahead as these medicines could face new clinical tests, more scrutiny
Markets recovered in late trades, amid firm European cues, led by rebound in financials and gains in IT shares.
A group of retired civil servants also called upon the PM to reach out to the families of the victims in Unnao and Kathua and "seek their forgiveness on behalf of all of us".
In a surprise announcement in April, Sun and Ranbaxy -- at that time owned by Japan's Daiichi -- declared an all-stock deal to create India's largest and world's fifth-largest drugmaker in an over $4 billion deal.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances